PT Prodia Widyahusada Tbk (PRDA) Fair Value & Analysis
Healthcare · ID · Market cap 2.1T IDR
Fair value as of: Jun 25, 2026
Analysis
PT Prodia Widyahusada Tbk (PRDA) currently trades at 2,600 IDR, while our model-based Fair Value estimate is 4,978 IDR — implying the stock looks roughly 91.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
PT Prodia Widyahusada Tbk provides clinical laboratory services in Indonesia. The company offers test services, such as genomic, laboratory, and non-laboratory tests, as well as test panels; doctor consultation and teleconsultation services; vaccines; home services; and research support services. It also engages in the operation of Prodia Health Care, a personalized medicine-based wellness clinic; and specialty clinics, including Prodia Children, Prodia Women, and Prodia Senior. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Prodia Widyahusada Tbk operates as a subsidiary of PT Prodia Utama.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PT Prodia Widyahusada Tbk (PRDA) undervalued?
What is the fair value of PRDA?
What is the quality score of PRDA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.